In this large-scale, multinational, descriptive survey, we sought to identify measures for improving treatment outcomes for individuals with epilepsy. As a framework, questions relating specifically to each of the five steps of the 'patient-physician journey', namely, patient identification (omitted in this survey), diagnosis, choice of drug, disease and drug information, and patient monitoring were asked. Overall, 337 physicians and 1150 patients across France, Germany, and the United States returned questionnaires. Results indicated that 16% of the patients were initially misdiagnosed. Treatment choice was driven by efficacy, safety, experience with a drug (physician only), and convenience (patient only). Physicians were identified as the primary source of information for patients, and, as expected, better informed patients were found to adhere better to their therapy than those who were less well informed. Approximately 50% of the patients had not seen their specialist in the last year, which indicates poor follow-up; furthermore, important topics such as seizures, treatment, and its side effects were not discussed at every visit. Specialists, but not primary care practitioners (PCPs), consistently reported discussing all topics more frequently than their patients, suggesting that specialists may overestimate the clarity of their questions. There was also substantial disparity in the reasons cited for nonadherencepatients overwhelmingly cited forgetfulness, while both PCPs and specialists cited complacency, forgetfulness, and tolerability. We also noted a disparity between physicians and their patients, as well as between PCPs and specialists, in their views on the impact of epilepsy on patients' lives. Our results indicate multiple opportunities to intervene at all stages of the patient-physician journey to improve treatment outcomes. We provide practical suggestions to achieve the most from these opportunities.
Introduction
Epilepsy is one of the most common neurological disorders worldwide, yet it remains poorly understood. It is frequently misdiagnosed, and treatment outcomes for many people living with epilepsy are suboptimal. It is also associated with significant, negative psychosocial consequences given the perceived stigma and everyday challenges associated with living with epilepsy [1, 2] . Given that the various aspects of the disease are relatively unique to individual patients, understanding these unique aspects -for example, specific triggers of seizures, particular needs in maintaining seizure control, and managing the psychosocial impact -can be difficult for patients and their physicians alike [2] .
The management of epilepsy or any other chronic disease typically represents a feedback loop composed of five steps, which could be seen as the 'patient-physician journey'. The five steps are the following: patient identification, diagnosis, choice of drug treatment, disease and drug information, and patient monitoring (Fig. 1) . Effective navigation through the five steps of this 'patient-physician journey' is important for achieving optimal outcomes.
This five-step model informed the structure and content of the survey described here, with questions designed to elicit information specifically relating to each of the management steps. While numerous surveys have been conducted with the aim of providing insight into perceptions of people with epilepsy (PWE) and physicians on the specific challenges of epilepsy and their preferences in managing the disease, most have focused on PWE and physicians separately [2, 3] . From the patients' perspective, there is a clear preference for receiving clear information on their disease as well as attention from the HCP to their nonclinical needs, and opportunities for improved patient-physician communications have been identified [4] . In an Indian survey, a significant positive correlation between effective doctor-patient communication and compliance was observed [5] . We identified one study where both PWE and their respective physicians were included in a linguistic survey study, assessing the dialogue between neurologists and their patients during real-life visits [6] . Although it was a small-scale study, with only 20 neurologists and 60 of their patients, encouraging results were obtained when using a questionnaire to improve management of side effects and common comorbid conditions.
To our knowledge, the survey described here is one the largest of its kind. When designing the survey, it was assumed a priori that mismatches in perceptions and expectations between patients and physicians may potentially lead to suboptimal treatment outcomes. Therefore, the objectives of our study were to identify points of divergence on epilepsy management between patient and physician, to indicate the stage at which these divergences are more likely to occur, to suggest potential measures to improve patient outcome, and, finally, to identify possible knowledge gaps. We included both specialists and primary care practitioners (PCPs) in the survey to identify opportunities for intervention in different health-care settings.
Methods

Study design
The study employed a cross-sectional design based on a quantitative, descriptive survey. The survey was administered in France, Germany, and the United States through the market research company InforMed Insight, UK.
The three-part survey questionnaire was developed by the authors. It was written in English and subsequently translated into German and French. The questionnaire was back translated and tested for content validity by local language and market research experts. The first two parts were completed online by physicians; part 1 pertained to physician knowledge and practice of epilepsy, diagnosis, and treatment while part 2 pertained to patient-specific information and their interactions with patients. Physicians were requested to complete the questionnaire for each individual patient seen consecutively in their practice (with a maximum of seven patients during their scheduled visits). The third part of the questionnaire was paperbased and was completed by patients during visits to their physician's office. Questions were related to the patient's overall experience of living with epilepsy, including treatment, sources of information, and interactions with their physician. Patient questionnaires (part 3) were linked to their physician's questionnaire (part 2) using an anonymous number linkage system. Three sets of survey questions were asked of both physicians and patients: the impact of epilepsy on patients' lives (nine domains), topics discussed during consultation, and adherence to therapy. For the question relating to the impact of epilepsy, both physicians and patients were asked to choose a score from 1 to 7 for each of the nine domains, with 1 indicating very little impact and 7 extremely negative impact. Scores 5, 6, and 7 were combined to provide an overall view on the negative impact of epilepsy on a given domain.
Ethical approval
Given the nature and content of the survey, approval by an ethics committee was not required. Patients were free to choose to participate or not, and those who chose to do so were provided with an information sheet and a consent form before being asked to complete the questionnaire. The information sheet stated the purpose of the study and the names of the sponsors. It also indicated that the survey was anonymous and confidential and that there would be no repercussions for choosing not to participate. Physicians were not given access to the responses of their patients.
Participants
Physicians were randomly selected from national market research databases. Both PCPs and specialist physicians -neurologists and epileptologists -were included in the study. Primary care practitioners were required to see at least five PWE per month, while specialists were required to see at least 10 PWE per month. The inclusion criteria for patients were the following: (1) diagnosed with epilepsy and (2) aged 18 years or older.
Data collection and analysis
Questions were specifically based on steps 2-5 identified in the conceptual framework; step 1, the identification of new patients, was not included in the survey as only already diagnosed patients were part of the survey. Physicians and patients were asked corresponding questions in order to identify divergent perceptions about the impact of variables relating to quality of life, as well as the topics discussed in the last patient consultation. Data entry was carried out by InforMed Insight, and all data were subject to two-pass verification. Analyses were carried out by InSites Consulting (using SPSS 19™ and STAT/SE 12™) and included descriptive statistics, chi-squared testing, and t-tests for the comparisons of physician and patient responses on matched survey questions. Statistical significance was set at the 5% level.
Results
Characteristics of participants
A total of 337 physicians and 1150 patients agreed to participate in the study (Table 1) . Physicians were in medical practice for a median of 16 years (4-30 years). Of the 337 physicians included in the study, 113 were from France, 110 were from Germany, and 114 were from the United States. Physicians reported practicing as neurologists (n = 110, 33%), epileptologists (n = 20, 6%), or PCPs (n = 207, 61%).
The median age of patients was 46 years (18-98 years), and 50% were female. In terms of occupation, just under half were employed (48%, 36% full-time and 12% part-time), 19% were unemployed (8% specifically due to their condition), 8% were students, 20% had retired, and 4% reported 'other'. The median time since patients had received a diagnosis of epilepsy was 14 years (1-65 years); the majority (61%) had received the diagnosis 10 years or more previously. Fiftyfive percent of the patients had a diagnosis of primary generalized epilepsy, and 40% of the patients had a diagnosis of focal epilepsy. Approximately three-quarters (879/1150) of patients (76% in Germany, 71% in France, and 79% in the US) were using monotherapy to control their seizures. Most reported good seizure control; 46% had experienced no seizures in the past 12 months, and 44% had experienced fewer than five seizures. Only 9% of the patients reported poor seizure control, defined as having experienced more than five seizures in the past 12 months. Almost all patients (96%) were being treated with AEDs.
On average, patients had received 1.4 other treatments (defined as either a switch in monotherapy, as well as addition of another AED, or a change in combination therapy) before the current treatment regimen; 35% had one prior treatment, and 29% had two.
Impact of epilepsy on patients' lives
There were several important differences in the answers provided by patients and physicians when asked to identify domains most affected by epilepsy and its treatment. Overall, there was a relatively good match in the responses given by patients and PCPs, with only two domains of statistically significant mismatch (both p b 0.05; Fig. 2a ). Primary care practitioners overestimated the impact of epilepsy on cognitive function -31% (95% confidence interval 28%-35%) of PCPs reported that epilepsy had a negative impact on cognitive function, while only 15% (95% CI 12%-18%) of patients did so. In contrast, PCPs underestimated the negative impact of epilepsy on the ability of patients to work or study (18% [15%-20%] vs 36% [32%-40%]).
There were a greater number of mismatched domains between specialists and their patients compared with PCPs and their patients (Fig. 2b) Given the differences between the responses given by PCPs and specialists, a post-hoc analysis was conducted to further compare the views of the two physician groups (Fig. 2c) . In terms of patient responses, there was an overall trend for patients consulting their specialists to give higher scores on the negative impact of epilepsy on the various quality-of-life domains compared with those visiting their PCPs. In one particular domain, the ability to work/study, however, there was substantial disparity between their responses, with a greater percentage of patients visiting specialists (51% [45%-56%]) reporting the negative impact of epilepsy on this domain compared with patients visiting PCPs (36% [32%-40]).
Patient identification
The design of the survey did not allow for the identification of new patients. Only those individuals with a confirmed diagnosis of epilepsy were included in the survey.
Diagnosis
Sixteen percent of patients were initially misdiagnosed. There were no differences across physician groups or countries in terms of mean misdiagnosis rates; however, 5% of the PCPs and 6% of the neurologists reported misdiagnosis rates exceeding 30% in contrast to none of the epileptologists. Patient diagnosis (by seizure type) varied considerably by physician specialty. Primary care practitioners reported a greater proportion of patients diagnosed with primary generalized seizures compared with specialists (epileptologists and neurologists combined; 46% vs 27%); conversely, specialists reported a greater proportion of patients diagnosed with focal epilepsy.
Treatment choice
As mentioned in Section 3.1, most patients (76.4%) were receiving monotherapy. If response to monotherapy was deemed to be suboptimal, the majority of PCPs (69%) across the three countries prescribed a second AED as monotherapy before initiating adjunctive therapy. Only 17% initiated adjunctive therapy after suboptimal response to the first monotherapy; 7% prescribed three monotherapy agents before initiation of adjunctive therapy, while 6% reported that they do not prescribe adjunctive therapy. Specialists had a choice of responding differently to the question according to seizure type. For patients with focal epilepsy, adjunctive therapy was initiated after suboptimal response to one, two, three, four, or ≥5 monotherapies by 16%, 62%, 19%, 2%, and 1% of the specialists, respectively. Corresponding numbers for patients with primary generalized seizures were similar; adjunctive therapy was initiated after suboptimal response to one, two, three or four monotherapies by 14%, 62%, 22% and 1% of the specialists, respectively, while a further 1% reported that they do not prescribe adjunctive therapy.
The main AED attributes driving the choice of treatment were similar for patients and physicians alike. When the physicians and patients were asked to rank the attributes on a scale of one to seven, efficacy was the dominant factor (ranked first by 92% of the physicians and 91% of the patients), followed by safety and tolerability (ranked second by 91% of the physicians and 86% of the patients). 'Experience with the AED' was ranked third by the physicians (81%), while 'convenient to take' was ranked third by the patients (77%).
Treatment change refers to a switch in monotherapy, addition of adjunctive therapy, or change in combination of AEDs. Of the patients (65%) who had changed treatment at least once, 38% had done so within the last 24 months. Approximately one-quarter of patients (27%) reported having requested treatment change at some point since starting AED treatment. From the patients' perspective, the most common reasons for treatment change were unwanted side effects (57%) and breakthrough seizures (41%). The reason physicians gave most often was lack of efficacy.
Disease and drug information
Patients reported obtaining information about epilepsy and treatment options from a variety of sources, most often from doctors (88%), friends and family (63%), the Internet (53%), and books (43%). Doctors and patients agreed fairly well on how informed the patient was on various aspects of epilepsy.
Monitoring and follow-up
Just under half of the patients (49%) saw their physicians on a quarterly basis following initial diagnosis. In the US, PCPs reported that onethird of their patients had not been seen by a specialist in the last year, while, in Germany and France, this applied to N 50% of the patients. The most common reasons for consultations were for a routine follow-up (64%) or for obtaining a repeat prescription (51%). When PCPs and specialists were asked to describe the topics they discussed during consultations with their patients, a different pattern between them emerged (Fig. 3 ). There was a good match between PCPs and their patients in terms of the topics they reported discussing. For example, 68% of the PCPs and 69% of their patients reported discussing 'how they are [patients] feeling'; corresponding figures were 51% for both PCPs and patients who reported discussing 'seizures and symptoms' (the second most frequent topic) and 49% and 48% for 'epilepsy medication' (the third most frequent topic) during every consultation (Fig. 3A) . In contrast, specialists consistently overestimated discussing topics by a relatively large margin (Fig. 3B) . The greatest disparity in the responses given by specialists and their patients was related to treatment tolerability/side effects; 66% of the specialists reported discussing this topic during all consultations, while only 35% of their patients reported doing so.
In terms of treatment adherence, once again, there was a good match between PCPs and their patients in the responses (Fig. 4) . Primary care practitioners were aware of adherent patients; 53% of the PCPs and 55% of their patients reported always taking their medication. In contrast, while 60% of specialists' patients reported full adherence to therapy, only 48% of specialists thought that their patients did so.
When both groups of physicians were asked about the reasons for nonadherence, their responses were similar (Figs. 5a and b) . The majority of PCPs (64%) and specialists (69%) reported that the most common reason for nonadherence was complacency, followed by side effects (61% and 51%, respectively) and forgetfulness (40% and 44%, respectively). However, the most common reason patients gave for not taking their medication was forgetfulness; 64% for patients treated by PCPs and 66% for those treated by specialists (Figs. 5a and b) , and neither complacency nor side effects were major reasons given by patients for not taking medication.
Being well informed contributed substantially to treatment adherence; 64% of the patients who felt well informed about their disease said that they always took their medication compared with 46% of those who did not feel well informed. However, physicians did not perceive this association between being well informed and adherence.
As continuous monitoring and follow-up of patients are needed in reassessing the impact of epilepsy management on their outcomes, patients with a low frequency of visits but demonstrating poor adherence or reporting poor treatment results may be in need of intervention, thereby closing the feedback loop as evident in Fig. 1 . In a post-hoc analysis, this subpopulation of patients was identified based on the analysis described in the schematic below (Fig. 6) . We identified 213 patients who fell into categories associated with poor seizure control, poor AED tolerability, and low QoL or low satisfaction/poor adherence to treatment. However, they saw their health-care provider fewer than three times a year, and most had no treatment change in the past 2 years.
Discussion
Results of this large-scale, multinational survey provide substantial insight into the impact of epilepsy and its treatment on patients' lives from the perspective of both patients and their treating physicians. There was substantial disparity in the views of the two groups when evaluating the impact of epilepsy on various life domains, as well as in their responses to questions related specifically to the patient-physician journey. Our findings provide the foundation for practical suggestions to improve treatment outcomes for PWE.
Impact of epilepsy on patients' lives -divergence of patient and physician views
Given the important impact of QoL in driving treatment decisions, we started by looking at the impact of epilepsy on patients' lives. Here, significant differences were noted between patients and their physicians in terms of the QoL domains most affected by epilepsy and its treatment. That patients and physicians are often not in agreement when assessing quality-of-life measures has been well documented in the literature with respect to: measures of anxiety and depression among cancer patients [7] ; psychological concerns of cancer patients [8] ; and the assessment of QoL in patients with chronic disease [9] , and following stroke [10] . Studies in which some significant level of agreement was found report that disagreement increases with the level of cognitive impairment [10] and that there is a U-shaped concordance between level of agreement and performance status (defined as the patient's level of functioning based on measures of activity, ambulatory status, and need for care) [11] . Greater disagreement has been reported on subjective measures of distress and anxiety [12] , as well as fatigue and social functioning [9] .
In our survey population, we found that for both groups of patients (those consulting their PCPs or specialists) the ability to work/study was ranked as the most strongly impacted domain by a large margin. Physicians, on the other hand, significantly underestimated the impact of epilepsy on this domain, especially specialists. While 51% of the patients reported that epilepsy had a negative impact on the ability to work/study, only 14% of the specialists did so -a difference of 37 percentage points. Corresponding values were 36% and 18% for PCPs and their patients, respectively. While the difference of 18 percentage points is less than that observed between specialists and their patients, it still remains an important difference. Interestingly, there was a substantial difference in the responses of the two groups of patients as well. More patients consulting their specialists reported that epilepsy had a negative impact on their ability to work/study compared with those consulting their PCPs. While this was the domain with the greatest disparity in the responses given by the two groups of patients, there was an overall trend for patients consulting specialists to give higher scores to the remaining domains. This observation could indicate that patients visiting specialists had more severe or difficult-to-control seizures compared with those visiting PCPs.
For both groups of physicians, the domain most negatively impacted by epilepsy was cognitive function. Once again, there was a significant mismatch with their patients, with fewer patients overall reporting epilepsy having a negative impact on cognitive function. Similarly, the extent of the mismatch was greater between specialists and their patients compared with PCPs and their patients. The impact of epilepsy on cognition can be difficult to recognize by patients, and physicians may be able to detect this more clearly than patients themselves. Indeed, as reported previously, cognitive deficits tend to be underreported by patients [13] ; furthermore, patients may have different concepts of cognition than physicians, which can lead to misunderstandings [14] . It is important to note that for patients, the impact on sleep was also a main concern -especially those visiting PCPs -and it is well recognized that epilepsy-related sleep disruption affects many aspects of life, including cognitive function. Therefore, patients may have attributed any cognitive impairment to sleep disturbances, rather than to the disease or adverse effects (AEs) of AEDs.
Overall, there were more mismatched domains with specialists than with PCPs (four vs two). In light of this result, we conducted a post-hoc analysis to gain further insight into the differences between the two groups. There were four notable differences; relative to PCPs, specialists attributed greater impact of epilepsy on cognition, but undervalued its impact on emotional well-being, sleep, social relationships, and leisure activities. This finding -greater mismatch with specialists than with PCPs -was observed in other analyses in our survey (see below).
In the second part of the analyses, participants' responses to questions related specifically to the various steps of the patient-physician journey were evaluated. The first step -patient identification -was not evaluated in this study.
Diagnostic challenges
With regard to the second step, diagnosis (rediagnosis), our survey revealed that the mean misdiagnosis rate was 16%, which is consistent with findings of other studies. In a study conducted in the UK, the misdiagnosis rate was also found to be 16% [15] ; however, rates of up to 30% have also been reported [16, 17] . In our survey, only PCPs and neurologists reported misdiagnosis rates exceeding 30% of their currently treated patients with epilepsy, indicating the importance of referral to specialist centers in cases of diagnostic doubt, as well as continuing education for physicians to review diagnostic challenges. Furthermore, epilepsy is almost unique among common medical disorders in that diagnosis is usually made entirely on the basis of the history [18] . This observation emphasizes the importance of good communication skills, which will encourage patients, family members, or friends to recount events accurately [18] . Poor response of seizures in some patients to their prescribed AED should also raise the index of suspicion for misdiagnosis, thereby prompting rediagnosis. A simple step such as repeating the diagnostic procedure could provide an explanation for treatment resistance, resulting in treatment change and improved response for some patients.
Factors driving choice of treatment
In our survey, there was good agreement between patients and physicians in the factors that drive the choice for treatment. The choices were, as expected, driven by efficacy, safety, prior experience with a drug (physician), and convenience (patient). While such factors are clear in the case of newly diagnosed patients, findings from the final step, 'monitoring and follow-up', indicate that the decision-making process when treatment change is required is not so clear-cut given the challenges identified in patient-physician communication. As expanded further below, factual parameters such as efficacy, safety, and QoL were not discussed adequately and, importantly, not at every visit, potentially leading to missed opportunities to further improve patient outcome. In a European survey of PWE and physicians conducted to gauge the level of satisfaction with current treatment strategies, there were notable differences between them when making treatment decisions [3] . Notably, factors related to avoiding AEs such as depression, anxiety, and behavioral changes and reducing titration period were all viewed far more importantly by patients than physicians. It must be noted, however, that patient and physician responses were not matched in that survey. In another study, patients were asked to identify which AED treatment outcomes they considered most important: reduction in seizure frequency was the most highly ranked treatment outcome in all three groups included in the study (i.e., recent diagnosis, established diagnosis, and women of childbearing age) [19] .
Sources of information
In the next step, we looked at the various sources patients used to obtain disease-related information. While there is some evidence indicating that patients consult the Internet to obtain such information, it is important to note that patients in our survey overwhelmingly reported their physicians as their primary source of information (88% vs 53% for the Internet). Other studies have also identified physicians as the main source of information [3, 20] . As expected but reassuring, nonetheless, better informed patients were found to adhere better to their therapy compared with patients who were less well informed. These observations indicate that physicians are ideally placed to provide valuable information to their patients on all aspects of the disease, enabling them to manage their condition more effectively. However, physicians rarely have time to provide adequate information -in this survey, the average consultation time was 32 min for newly diagnosed patients and 17 min for follow-up visits. Average time spent in consultation, by region, for those with newly diagnosed epilepsy was 29, 30, and 36 min in France, Germany, and the US, respectively; corresponding values for follow-up consultations were on average 17, 15, and 20 min. In the patient-physician survey by Gilliam and colleagues, the mean consultation time was even shorter at 12 min [6] . Given the limited amount of time available during consultations, it would be helpful if physicians could guide their patients to validated sources of information, whether on the Internet, or printed material, or other health-care providers such as specialist nurses and counselors. In this respect, physicians should perhaps see themselves as the gatekeepers, rather than providers of information. Yet, in this survey, only 6% of the physicians mentioned having an epilepsy nurse as support.
The Internet may be a valuable resource for some patients, and a study to determine the user profile of those who find it most useful would be informative. Also, whether the use of the Internet results in greater dissatisfaction with treatment, or whether dissatisfied patients use the Internet more, could not be determined. However, it is clear that the use of online resources can be of benefit to some PWE (see below).
Monitoring and follow-up
Our main findings focus on the fifth step, given that epilepsy is a chronic condition and necessitates long-term follow-up. Consultations provide the opportunity for patients and physicians to review the status quo and to either maintain it or change it. However, our findings reveal many missed opportunities. Foremost, approximately 50% of the patients in this study had not seen their specialist in the last year, which indicates inadequate follow-up. It is not clear if follow-up programs, information, and/or instructions in epilepsy are as well developed as those for other serious chronic diseases, such as diabetes and cancer. It is advisable that PCPs and patients agree on a revisit protocol and an understanding of when to recontact; it is not sufficient to ask patients to call if they are having problems without defining the problems that need physician's attention. Notably, we identified a not insignificant subgroup of patients (19%) who were in need of intervention. These patients were identified based on their reports of poor seizure control, poor AED tolerability, or low QoL, as well as low satisfaction/poor adherence to treatment. However, they saw their health-care provider fewer than three times a year, and most had no treatment change in the past 2 years.
Patient-physician dialogue
Our findings also shed light on why opportunities are missed. When asked to report discussion topics during consultations, important topics such as seizures and treatment side effects were not discussed at every visit.
There were pronounced disparities between specialists and their patients in their perception of topics discussed in all consultations but not between PCPs and their patients. Specialists substantially overestimated discussing important topics such seizures and symptoms, medication, and its side effects. Quality of life was the only topic reported by a similar but small proportion of specialists and their patients to be discussed at every consultation (32% and 30%, respectively). In contrast, there was an excellent match between PCPs and their patients in the reporting of discussion topics. The greatest disparity between their responses related to QoL, where interestingly patients, rather than the PCPs, overestimated discussing this topic at every visit (42% and 35%, respectively). Despite the good match, the proportion of both PCPs and patients reporting discussing specific topics was much smaller than that of both specialists and their patients. Fewer PCPs and their patients reported discussing 'how are you feeling', seizures and symptoms, medication, and its side effects at every consultation compared with specialists and their patients. These observations suggest that specialists may overestimate the clarity of their questions, that PCPs may not question their patients enough, and that some patients take in information on certain topics less well than on others.
In the aforementioned European survey, PWE and physicians also had differing views on what was discussed during consultations [3] . Asking clear, unambiguous questions such as "how many seizures have you had since we last met" is clearly preferable to asking the question "how have you been". Indeed, the importance of these missed opportunities is such that documentation of seizure type and frequency is the first of eight epilepsy quality measures developed by the American Academy of Neurology [21] . According to the authors, when patients report that they are "doing well," they may not mean that they are seizure-free, but rather that they have the same seizure frequency as before. In a survey of PWE using a web-based epilepsy community, 60% of the respondents cared for by PCPs reported that their physician asked them how many seizures they had (for each type of seizure they experience) since their last visit [22] . Corresponding figures for epileptologists and neurologists were 91% and 94%, respectively. Therefore, it is imperative to ask PWE direct questions in unambiguous terms in order to assess current seizure control and other important issues such as the impact of AEs of treatment. People with epilepsy have been reported to be reluctant to discuss AEs with their physicians and relied on them to raise such issues; correspondingly, physicians report that many patients are not proactive [3] . A specific checklist to complete rather than a 'free-floating' discussion could be of value, as would providing patients with the opportunity and assistance to learn how to recognize issues and problems with their treatment [23, 24] .
Identifying and addressing reasons for nonadherence
Another important aspect of monitoring patients with chronic diseases is to ascertain their adherence to their therapeutic regimen. Treatment adherence is essential for preventing breakthrough seizures and potentially life-threatening events such as status epilepticus. In the RANSOM study, nonadherence was associated with a greater than threefold increased risk of mortality compared with adherence [25] . Consequently, identifying and addressing reasons for nonadherence is an essential aspect of the patient-physician dialog.
In our survey, PCPs and their patients mostly agreed on the extent but not on the reasons for treatment nonadherence, while specialists and their patients agreed on neither the extent nor the reasons. Patients overwhelmingly cited forgetfulness, while physicians cited complacency, forgetfulness, and tolerability most frequently. The issue of treatment adherence in epilepsy is complex, given that PWE only experience symptoms (i.e., seizures) sporadically but are required to take medications on a daily basis for many years [26] . Since the consequences of nonadherence may not appear immediately, PWE may conclude erroneously that rigorous adherence to their treatment regimen is not important [26] . Furthermore, nonadherence can lead to detrimental clinical decisions if the reasons for nonadherence are not thoroughly and thoughtfully questioned, e.g., changing a drug that could have potentially been very effective or increasing the dose leading to severe AEs or even to a misdiagnosis of drug-resistant epilepsy [27] . The reasons or predisposing factors for nonadherence are numerous; even variation in the appearance of tablets has been shown to be significantly associated with nonadherence in epilepsy [28] . Forgetfulness has been cited as the most frequent reason for nonadherence in epilepsy and in chronic diseases in general [29] [30] [31] [32] . However, it is important to determine why patients forget. Nonadherence is rarely due to a single factor; therefore, even if one factor is successfully addressed, the problem may still persist. Addressing the issues related to each of these factors is necessary if patients' adherence to therapies is to be improved [33] . According to the World Health Organization, the mismatch between the patients' 'readiness' and the physicians' attempts at intervention means that patients will most likely not adhere to prescribed therapy [33] . Therefore, the role of physicians in ensuring adherence is paramount -they need to be able to assess the risk of nonadherence, evaluate the patient's readiness to adhere, advise them on how to do so, and follow up on their progress at every contact [33] .
As with many other chronic diseases, self-management in epilepsy should be encouraged. Self-management should be viewed as a partnership between the person and the health-care provider -in this partnership, the patient recognizes that chronic conditions require medical services and assistance from a clinician, and the health-care provider recognizes that the expert in the day-to-day challenges of management is the patient [34] . Physicians should involve themselves in the process of self-management, monitoring, and follow-up as this may potentially provide opportunities to adapt treatment and encourage behavioral improvements.
Study limitations
The major limitation of the study is that the survey reports subjective perceptions of QoL and did not employ objective measures or standardized scales. Comparisons of subjective assessments (i.e., those of patients) with the potentially more objective assessments (i.e., those of physicians) should not be used to suggest that one is more valid than the other. Patients have their personal experience and perhaps that of acquaintances, friends, and family as points of reference, whereas physicians have the broader perspective resulting from seeing many patients with epilepsy. To illustrate this, physicians rated cognitive functioning as being more affected by epilepsy than did patients. Physicians may be able to observe the effect on cognitive function more clearly compared with patients themselves. Conversely, ability to work/study appeared to be the main concern of patients. Additionally, the survey was administered in high-income countries; as such, the results may lack transferability to low-or medium-income country contexts. Finally, the Hawthorn effect (placebo effect) of the survey itself cannot be ruled out both in the case of physicians and patients -in the case of patients, the mere fact that they were participating in the study may have improved their subjective assessment of the outcomes of interest; alternately, the fact that physicians were similarly a part of the study may have altered their perceptions of their patients' outcomes.
Conclusions
The results of this survey reveal many missed opportunities to improve outcomes for PWE starting from diagnosis ( Table 2) . One in six patients were found to be initially misdiagnosed; since timely and accurate diagnosis is the first step toward managing the disorder, education on the diagnosis of epilepsy and protocolled disease status monitoring for physicians could contribute to improved patient outcomes. The Table 2 Potential interventions to improve outcomes among individuals with epilepsy at the various steps of the patient-physician journey.
Diagnosis/rediagnosis
• Continuing education -review of diagnostic challenges
• Improvement of communication skills in order to encourage patients to recount events accurately
• Poor response to prescribed therapy -index of suspicion for misdiagnosis should prompt rediagnosis Treatment -drug choice and adaptation • Discuss factual parameters such as treatment efficacy, tolerability, and impact on quality of life at every visit to determine whether treatment change is required Disease and drug information • Given the lack of time during consultations, physicians should be the gatekeepers rather than providers of information -they should guide their patients in terms of the following:
○ Validated sources of information whether on the Internet or print material ○ Other health-care providers such as specialist nurses and counselors
Monitoring and follow-up
• Agree on a revisit protocol and an understanding of when to contact; it is not sufficient to ask patients to call if they are having problems without defining the problems that need physician's attention
• Provide patients with the opportunity and assistance to learn how to recognize issues and problems with their treatment
• Ask direct, clear questions in unambiguous terms in order to assess current seizure control and other important issues such as the impact of adverse effects of treatment
• Developing a specific checklist to complete rather than a 'free-floating' discussion could be of value
• Forgetfulness has been cited as the most frequent reason for nonadherence; however, it is important to determine why patients forget to take their medicine
• Nonadherence is rarely due to a single factor; therefore, even if one factor is successfully addressed, the problem may still persist. Addressing the issues related to each of these factors is necessary if adherence is to be improved
• Encourage self-management ○ Explain clearly that self-management is a partnership between the patient and the health-care provider -while epilepsy requires medical services and assistance from a clinician, the expert in the day-to-day challenges of management is the patient choice of treatment is driven by the same factors for both physicians and patients -efficacy, safety, experience with a drug (physician), and convenience (patient). While such factors are clear in the case of newly diagnosed patients, important treatment decisions for patients who have been living with the condition may not be so clear for a number of reasons: poor follow-up, lack of clarity in the discussions/questions during follow-up visits, and disparity in the reasons provided for nonadherence to treatment.
Although not a primary objective of this study, our results also showed disparity between PCPs and specialists in their views on the impact of epilepsy on patients' lives. Primary care practitioners reported a greater overall negative impact on patients' lives compared with specialists. Primary care practitioners also appeared to be more 'in tune' with patients, as demonstrated by the almost perfect match between their answers and their patients when asked about topics of discussion during visits, as well as better view on the extent of treatment adherence by patients. Based on these observations, PCPs appear to have a more holistic view of their patients' condition. A close interaction between PCPs and specialists could lead to a greater improvement in some dimensions of the QoL of patients and the overall quality of care.
In conclusion, there are structural opportunities for intervention identified in every step of the patient-physician journey, and physicians are encouraged to take a step back in their daily practice to see how best these interventions can be implemented by the team. It is of fundamental importance to recognize that the successful treatment of PWE depends not only on the time spent in the doctor's office but also on appropriate monitoring and follow-up, as well as a detailed plan and protocol for communication between patients and physicians over the long term.
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